AZN Share Price

Open 4450.00 Change Price %
High 4509.98 1 Day -150.00 -3.36
Low 4297.50 1 Week -290.50 -6.30
Close 4318.50 1 Month 17.00 0.40
Volume 5682885 1 Year 56.50 1.33
52 Week High 5505.00
52 Week Low 3680.00
AZN Important Levels
Resistance 2 4515.47
Resistance 1 4434.30
Pivot 4375.33
Support 1 4202.70
Support 2 4121.53
LON UK Most Active Stocks
GGP 0.39 39.29%
GGP 0.39 39.29%
GGP 0.39 39.29%
FITB 0.30 -16.67%
FITB 0.30 -16.67%
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
LLOY 65.07 0.51%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MLD 10.00 700.00%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
LDP 0.03 50.00%
LDP 0.03 50.00%
OTC 0.03 50.00%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
NBR 0.25 -24.24%
More..

AstraZeneca PLC (LON: AZN)

AZN Technical Analysis 3
As on 20th Jan 2017 AZN Share Price closed @ 4318.50 and we RECOMMEND Sell for LONG-TERM with Stoploss of 4421.43 & Sell for SHORT-TERM with Stoploss of 4358.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
AZN Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
AZN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.astrazeneca.com
AZN Address
AZN
2 Kingdom Street
London, W2 6BD
United Kingdom
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151
AZN Latest News
Retreated Mix Cap Active Movers- AstraZeneca PLC (NYSE:AZN), Novo Nordisk A/S ...   Seneca Globe   - 17th Jan 17
what are Analysts report about: AstraZeneca PLC (NYSE:AZN)   News Oracle   - 17th Jan 17
Form 6-K ASTRAZENECA PLC For: Jan 17   StreetInsider.com   - 17th Jan 17
AstraZeneca plc 14.4% Potential Upside Indicated by Liberum Capital   DirectorsTalk Interviews   - 17th Jan 17
AstraZeneca sets new lung cancer trial deadlines   MarketWatch   - 17th Jan 17
AstraZeneca plc (AZN) Receives Buy Rating from Jefferies Group   Sports Perspectives   - 17th Jan 17
Astrazeneca PLC (AZN) Short Interest Update   Sports Perspectives   - 16th Jan 17
Revenue Growth Analysis of AstraZeneca PLC (NYSE:AZN)   FactsReporter   - 12th Jan 17
What are analysts Suggestions on: AstraZeneca PLC (NYSE:AZN)   News Oracle   - 09th Jan 17
Bryan, Garnier & Co Reiterates Buy Rating for AstraZeneca plc (AZN)   The Cerbat Gem   - 09th Jan 17
Interactive Technical Analysis Chart AstraZeneca PLC ( AZN LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AstraZeneca PLC
AZN Business Profile
AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. and FibroGen, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.